Company intelligence / Profile preview

INIBIC

Bucheon-si, Gyeonggi-do, South Koreainibic.es ↗

Ownership: Private
Employees: ~139
Development stage: Other

Overview

INIBIO has developed a botulinum toxin product that has received NDA approval from the Korean FDA and GMP approval for its manufacturing plant. The company has completed Phase 3 clinical trials in China and Korea and begun commercial distribution domestically as of late 2024. It has also executed exclusive distribution agreements with several countries including Thailand, Costa Rica, Kuwait, China, Peru, Brazil, and Taiwan.

Therapeutic areas: Dermatology
Modalities: Biologic (Botulinum toxin)Medical device (aesthetic devices)Small molecule (potentially for natural products; not explicitly detailed)
Industry: Biotech

Partnerships

Exclusive distribution agreements with partners/distributors in Thailand, Costa Rica, Kuwait, China, Peru, Brazil, Taiwan.

Beyond the preview

Go deeper on INIBIC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INIBIC.

Explore the full profile